[Photodynamic therapy in AMD. Strategy for indication].
In recent years several prospective studies have dealt with the therapeutic possibilities of PDT. In consideration of lesion size and its composition, a subtly differentiated scheme of therapy has been developed. Based on essential studies, recommendations on the indication for photodynamic therapy are summarized. They are complemented by references to safety and efficacy of photodynamic therapy. Users of PDT are given a short summary of relevant studies with current recommendations, which might ease the daily procedure of indicating photodynamic therapy.
Pauleikhoff
D
D
Augenabteilung, St. Franziskus Hospital, Münster. dapauleikhoff@muenster.de
Spital
G
G
D020256:Choroidal Neovascularization / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D010778:Photochemotherapy / Q000009:adverse effects; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011166:Porphyrins / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013997:Time Factors; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D010919:Placebos; D011166:Porphyrins; D000077362:Verteporfin